前言:5月14日,诺诚健华公布2025年1季报,报告显示总营收3.81亿元,实现净利润为1,797万元。企业成功扭亏为盈的背后,是核心单品奥布替尼的销售高速增长。这为中国生物创新药企业产品商业化困境揭开了一条破局之路。01奥布替尼快速放量诺诚健华扭亏为盈财报显示,2025年一季度企业总营收3.81亿元,同比增长129.9%,归属于上市公司股东的净利润为1,797万元,成功实现扭亏为盈。在一季度亮眼...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.